Create a free QxMD account to take advantage of the features offered by Read like saving your papers and creating collections.

Get Started

JOURNAL ARTICLE

Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir

Charlotte Charpentier, Bénédicte Roquebert, Olivier Delelis, Lucile Larrouy, Sophie Matheron, Roland Tubiana, Marina Karmochkine, Xavier Duval, Geneviève Chêne, Alexandre Storto, Gilles Collin, Antoine Bénard, Florence Damond, Jean-François Mouscadet, Françoise Brun-Vézinet, Diane Descamps

Antimicrobial Agents and Chemotherapy 2011, 55 (3): 1293-5

We studied seven heavily pretreated HIV-2-infected patients exhibiting a virological failure while receiving a salvage raltegravir-containing regimen. At the time of virological failure, different resistance genetic pathways were observed: T97A-Y143C, Q148K, Q148R, G140S-Q148R, E92Q-Y143R-N155H, and T97A-N155H. Thus, despite a 40% difference in integrase genes between HIV-1 and HIV-2, the genetic pathways leading to raltegravir resistance are similar.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not. Xiao-Ju Ni, Olivier Delelis, Charlotte Charpentier, Alexandre Storto, Gilles Collin, Florence Damond, Diane Descamps, Jean-François Mouscadet Retrovirology 2011, 8: 68

Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal. Charlotte Charpentier, Lucile Larrouy, Sophie Matheron, Florence Damond, Olivier Delelis, Jean-François Mouscadet, Pauline Campa, Geneviève Chêne, Françoise Brun-Vézinet, Diane Descamps Antiviral Therapy 2011, 16 (6): 937-40

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. C Charpentier, M Karmochkine, D Laureillard, P Tisserand, L Bélec, L Weiss, A Si-Mohamed, C Piketty HIV Medicine 2008, 9 (9): 765-70

Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance. Robert A Smith, Dana N Raugi, Nancy B Kiviat, Stephen E Hawes, James I Mullins, Papa S Sow, Geoffrey S Gottlieb AIDS 2011 November 28, 25 (18): 2235-41

Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. Signe Fransen, Soumi Gupta, Robert Danovich, Daria Hazuda, Michael Miller, Marc Witmer, Christos J Petropoulos, Wei Huang Journal of Virology 2009, 83 (22): 11440-6

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. Daniel da Silva, Liesbeth Van Wesenbeeck, Dominique Breilh, Sandrine Reigadas, Guerric Anies, Kurt Van Baelen, Philippe Morlat, Didier Neau, Michel Dupon, Linda Wittkop, Hervé Fleury, Bernard Masquelier Journal of Antimicrobial Chemotherapy 2010, 65 (6): 1262-9

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Isabelle Malet, Olivier Delelis, Marc-Antoine Valantin, Brigitte Montes, Cathia Soulie, Marc Wirden, Luba Tchertanov, Gilles Peytavin, Jacques Reynes, Jean-François Mouscadet, Christine Katlama, Vincent Calvez, Anne-Geneviève Marcelin Antimicrobial Agents and Chemotherapy 2008, 52 (4): 1351-8

Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Olivier Delelis, Sylvain Thierry, Frédéric Subra, Françoise Simon, Isabelle Malet, Chakib Alloui, Sophie Sayon, Vincent Calvez, Eric Deprez, Anne-Geneviève Marcelin, Luba Tchertanov, Jean-François Mouscadet Antimicrobial Agents and Chemotherapy 2010, 54 (1): 491-501

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. Isabelle Malet, Olivier Delelis, Cathia Soulie, Marc Wirden, Luba Tchertanov, Philippe Mottaz, Gilles Peytavin, Christine Katlama, Jean-François Mouscadet, Vincent Calvez, Anne-Genevieve Marcelin Journal of Antimicrobial Chemotherapy 2009, 63 (4): 795-804

In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. Charlotte Charpentier, Lucile Larrouy, Gilles Collin, Florence Damond, Sophie Matheron, Geneviève Chêne, Ting Nie, Raymond Schinazi, Françoise Brun-Vézinet, Diane Descamps AIDS 2010 November 13, 24 (17): 2753-5

Make the most of Read.
Download the mobile app.

Want full text access to this paper?

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir

Discussion

Related Papers

Want full text access to this paper?

Save your favorite articles in one place with a free QxMD account.

Read

Search Tips